tb31f
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 14, 2020 (NCT04238689)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- PlasmodiumImmunity, passive
Plasmodium immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06413108 | Phase 1/Phase 2 (Phase 2) | Jul 12, 2024 | Malaria Research and Training Center, Bamako, Mali, Radboud University, University of London |
| NCT04238689 | Phase 1 | Feb 14, 2020 | PATH, Radboud University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Radboud University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Malaria Research and Training Center, Bamako, Mali | Academic/Hospital | 1 | 0 | 1 | 2024 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1